{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:48Z","timestamp":1787721648110,"version":"build-2784847793"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of Edaravone Dexborneol in the treatment of acute ischemic stroke (AIS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized clinical trials (RCTs) and Prospective cohort study on Edaravone Dexborneol for AIS were retrieved from PubMed, Embase, Cochrane Library, Web of Science, and CNKI. The quality of included studies was assessed using the Cochrane risk of bias tool. Meta-analysis was performed using RevMan 5.2. Efficacy evaluation is based on the changes in the National Institutes of Health Stroke Scale (NIHSS) and mRS scores from baseline to 10\u201314\u202fdays after treatment, as well as the proportion of patients achieving a modified Rankin Scale (mRS) score of 0\u20131 at 90\u202fdays. Safety evaluation is based on the incidence of adverse events during treatment or within 3\u202fmonths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The meta-analysis included 54 studies. For efficacy evaluation: 1. Compared with the control group, the edaravone dexborneol (ED) treatment group showed a reduction in NIHSS score of 2.27, which was statistically significant (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f93%, MD\u202f=\u202f\u20132.27, 95% CI:\u20132.61 to\u20131.94,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.00001). Subgroup analysis based on the mean baseline NIHSS score categorized patients into mild-to-moderate, moderate-to-severe, and severe stroke subgroups. In the mild-to-moderate stroke subgroup: (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f91%, MD\u202f=\u202f\u20131.92, 95% CI:\u20132.30 to\u20131.54,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.00001.). In the moderate-to-severe stroke subgroup: (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f94%, MD\u202f=\u202f\u22122.76, 95% CI: \u22123.72 to \u22121.79,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.00001). In the severe stroke subgroup: (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f80%, MD\u202f=\u202f\u22123.50, 95% CI: \u22124.76 to \u22122.24,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.04). Patients with higher baseline NIHSS scores may have more pronounced functional improvement after ED treatment. 2. At 2\u202fweeks after treatment, the ED group showed a reduction in mRS score of 0.93 compared with the control group, with statistical significance (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f98%, MD\u202f=\u202f\u20130.93, 95% CI:\u20131.23 to\u20130.63,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.00001). 3. For the proportion of patients achieving mRS\u202f=\u202f0\u20131 at 90\u202fdays after treatment, 7 studies were included, with 4,925 patients in the ED group and 3,289 in the control group (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f57%, RR\u202f=\u202f1.10, 95% CI: 1.02 to 1.18,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.01). The results indicate a statistically significant functional improvement at 90\u202fdays after ED treatment for acute cerebral infarction. Therefore, ED may achieve both short-term and long-term neurological improvement in acute ischemic stroke. For safety evaluation, there was no statistically significant difference in the incidence of adverse events between the ED group and the control group (RR\u202f=\u202f0.99, 95% CI: 0.95 to 1.03,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.60).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides evidence supporting the efficacy and safety of Edaravone Dexborneol for both short- and long-term treatment of acute ischemic stroke. It significantly reduced NIHSS and mRS scores at 10\u201314\u202fdays post-treatment and increased the proportion of patients achieving an mRS score of 0\u20131 at 90\u202fdays. Patients with higher baseline NIHSS scores may derive greater prognostic benefit from edaravone dexborneol therapy. Future multicenter, large-sample clinical studies are still needed to further validate the efficacy and safety of Edaravone Dexborneol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1794547","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:48:40Z","timestamp":1787719720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of edaravone dexborneol for acute ischemic stroke: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinxiu","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Neurology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, China-Japan Union Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1016\/S0140-6736(24)00642-1","article-title":"Stroke","volume":"403","author":"Hilkens","year":"2024","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3238165","DOI":"10.1155\/2018\/3238165","article-title":"Stroke in the 21(st) century: a snapshot of the burden, epidemiology, and quality of life","volume":"2018","author":"Donkor","year":"2018","journal-title":"Stroke Res Treat"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1161\/STROKEAHA.110.596684","article-title":"Targeting the ischemic penumbra","volume":"42","author":"Ramos-Cabrer","year":"2011","journal-title":"Stroke"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/STROKEAHA.122.038466","article-title":"Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke","volume":"54","author":"Nie","year":"2023","journal-title":"Stroke"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/STROKEAHA.118.023927","article-title":"Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era","volume":"50","author":"Savitz","year":"2019","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1161\/STROKEAHA.121.034947","article-title":"Top priorities for cerebroprotective studies-a paradigm shift: report from STAIR XI","volume":"52","author":"Lyden","year":"2021","journal-title":"Stroke"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e2431","DOI":"10.1002\/brb3.2431","article-title":"Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: a meta-analysis","volume":"11","author":"Yang","year":"2021","journal-title":"Brain Behav"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/svn-2018-000221","article-title":"Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/fcp.12782","article-title":"Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2\/HO- 1 signaling pathway in mice","volume":"36","author":"Xu","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ejphar.2014.06.035","article-title":"The synergetic effect of edaravone and borneol in the rat model of ischemic stroke","volume":"740","author":"Wu","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaneurol.2023.5716","article-title":"Sublingual edaravone dexborneol for the treatment of acute ischemic stroke the TASTE-SL randomized clinical trial","volume":"81","author":"Fu","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.STR.0000182241.07096.06","article-title":"Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain","volume":"36","author":"Zhang","year":"2005","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.neuroscience.2010.11.029","article-title":"Protection by borneol on cortical neurons against oxygen-glucose deprivation\/reperfusion: involvement of anti-oxidation and anti-inflammation through nuclear transcription factor \u03baappaB signaling pathway","volume":"10","author":"Liu","year":"2011","journal-title":"Neuroscience"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"16:1589307","DOI":"10.3389\/fneur.2025.1589307","article-title":"Clinical efficacy of edaravone dexborneol in the treatment of acute ischemic stroke: meta-analysis","volume":"16","author":"Gao","year":"2025","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1649476","DOI":"10.3389\/fneur.2025.1649476","article-title":"Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and Meta-analysis","volume":"16","author":"Moghib","year":"2025","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2020.08.008","article-title":"Cochrane centralised search service showed high sensitivity identifying randomized controlled trials: a retrospective analysis","volume":"127","author":"Noel-Storr","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/STROKEAHA.120.031197","article-title":"Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.19335\/j.cnki.2096-1219.2021.20.045","article-title":"The efficacy of alteplase combined with edaravone dexborneol on acute ischemic stroke","volume":"7","author":"Zhang","year":"2021","journal-title":"Smart Healthc"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3969\/j.issn.1002-266X.2021.18.019","article-title":"Improvement of brain injury in patients with acute anterior circulation cerebral infarction with good intravascular recanalization by intravenous infusion of Edaravone Dexborneol","volume":"61","author":"Zhang","year":"2021","journal-title":"Shang Dong Yi Yao"},{"key":"ref20","first-page":"11","article-title":"Clinical observation of edaravone dexborneol in the treatment of acute cerebral infarction","volume":"12","author":"Tong","year":"2022","journal-title":"Cardiovasc Dis Prevent Knowl"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.12385\/j.issn.2096-1278(2022)10-0085-04","article-title":"Clinical observation of edaravone and dexborneol concentrated solution for injection on treatment of acute cerebral infarction","volume":"30","author":"Wang","year":"2022","journal-title":"Clin Res"},{"key":"ref22","first-page":"63","article-title":"Observation on the effect of early intravenous thrombolysis combined with edaravone and dextromethorphan injection in the treatment of acute ischemic stroke","volume":"62","author":"Lu","year":"2022","journal-title":"Shan Dong Yi Yao"},{"key":"ref23","first-page":"133","article-title":"Effects of edaravone dexborneol on neurological function, oxidative stress and inflammatory factors in patients with acute ischemic stroke","volume":"19","author":"Xia","year":"2022","journal-title":"J Hunan Normal Univ (Med Sci)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.16440\/J.CNKI.1674-8166.2023.04.05","article-title":"Therapeutic effects of edaravonedexborneol on acute cerebral infarction patient oxidative stress, vascular endothelial function, and prognosis","volume":"24","author":"Wu","year":"2023","journal-title":"Chronic Pathematol J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.13638\/j.issn.1671-4040.2023.15.030","article-title":"Efficacy of edaravone dexborneol injection in the treatment of acute ischemic stroke","volume":"23","author":"Deng","year":"2023","journal-title":"Pract Clin Integrat Chin Western Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.15887\/j.cnki.13.1389\/r.2023.28.012","article-title":"Clinical effect of edaravone dexborneol injection combined with intravenous thrombolysis in the treatment of acute ischemic stroke","volume":"16","author":"Li","year":"2023","journal-title":"Chin J of Clin Rational Drug Use"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3969\/j.issn.1007-614x.2023.20.022","article-title":"Therapeutic effect of edaravone dexborneol on moderate cerebral infarction patients within 48 hours after onset","volume":"39","author":"Jiang","year":"2023","journal-title":"Chin Commun Doct"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"20220312.1-9","DOI":"10.1515\/tnsci-2022-0312","article-title":"Effects of edaravone dexborneol on neurological function and serum inflammatory factor levels in patients with acute anterior circulation large vessel occlusion stroke","volume":"14","author":"Hu","year":"2023","journal-title":"Transl Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.36468\/pharmaceutical-sciences.spl.916","article-title":"Therapeutic role of edaravone dexborneol injection in acute ischemic stroke and its influence on nerve function","volume":"86","author":"Li","year":"2024","journal-title":"Indian J Pharm Sci"},{"key":"ref30","first-page":"118","article-title":"Efficacy of edaravone dexborneol concentrated solution for acute cerebral infarction","volume":"22","author":"Shao","year":"2024","journal-title":"J China Prescript Drug"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12883-024-03712-1","article-title":"Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Neurol"},{"key":"ref32","first-page":"30","article-title":"Effects of edaravone dexborneol on neurological function and inflammatory response in patients with acute atherosclerotic cerebral infarction","volume":"22","author":"Wang","year":"2025","journal-title":"North Pharm"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.14164\/j.cnki.cn11-5581\/r.2025.22.017","article-title":"Observation on the therapeutic effect of edaravone and dexborneol combined with butylphthalide in the treatment of acute cerebral infarction","volume":"19","author":"Gai","year":"2025","journal-title":"Chin J Mod Drug Appl"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3969\/j.issn.1006-4931.2025.12.020","article-title":"Clinical evaluation of edaravone and dexborneol combined with dual antiplatelet therapy in acute progressive cerebral infarction","volume":"34","author":"Liu","year":"2025","journal-title":"China Pharm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15887\/j.cnki.13-1389\/r.2025.34.001","article-title":"Clinical effect of edaravone dexborneol combined with butylphthalide in the treatment of acute cerebral infarction","volume":"18","author":"Liu","year":"2025","journal-title":"Chin J Clin Ration Drug Use"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14164\/j.cnki.cn11-5581\/r.2025.04.025","article-title":"Analysis of effect and safety of edaravone and dexborneol on oxidative stress factors in patients with acute cerebral infarction","volume":"19","author":"Ye","year":"2025","journal-title":"Chin J Mod Drug Appl"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3969\/j.issn.1672-0369.2025.07.005","article-title":"Effects of edaravone dexborneol concentrated solution for injection combined with alteplase intravenous thrombolysis on patients with acute cerebral infarction","volume":"37","author":"Li","year":"2025","journal-title":"Med J Chin People Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.11723\/mtgyyx1007-9564202501005","article-title":"Clinical efficacy of edaravone dextrocamphenol in patients with type 2 diabetes mellitus complicated with acute cerebral infarction","volume":"28","author":"Gong","year":"2025","journal-title":"Chin J Coal Ind Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3969\/ji.ssn.1674-0947.2025.01.013","article-title":"Edaravone dexborneol combined with butylphthalide in the treatment of acute cerebral infarction after intravenous thrombolysis","volume":"47","author":"Liu","year":"2025","journal-title":"J Shandong Med Coll"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e213949","DOI":"10.1212\/WNL.0000000000213949","article-title":"Clinical and safety outcomes of edaravone dexborneol in acute ischemic stroke a multicenter, prospective, cohort study","volume":"105","author":"Ma","year":"2025","journal-title":"Am Acad Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.19368\/j.cnki.2096-1782.2025.05.104","article-title":"Clinical effect of alteplase combined with edaravone dextrocamphorol in the treatment of acute cerebral infarction","volume":"10","author":"Sun","year":"2025","journal-title":"Syst Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15887\/j.cnki.13-1389\/r.2025.24.004","article-title":"Efficacy of edaravone and dexborneol combined with alteplase thrombolysis in the treatment of acute posterior circulation cerebral infarction and its impact on neurological function","volume":"18","author":"Yang","year":"2025","journal-title":"Chin J Clin Ration Drug Use"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3969\/j.issn.1004-2407.2025.05.002","article-title":"Effect of edaravone dexacamphene combined with butylphthalein on neuron protection, serum matrix metalloproteinase and chitinase protein 40 in patients with acute cerebral infarction","volume":"40","author":"Dong","year":"2025","journal-title":"J Northwest Pharm"},{"key":"ref44","first-page":"892","article-title":"Effect of edaravone dexborneol combined with low molecular weight heparin calcium on neurological function and serum inflammatory cytokines in patients with acute progressive cerebral infarction","volume":"49","author":"Wang","year":"2025","journal-title":"Gui Zhou Yi Yao"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.19368\/j.cnki.2096-1782.2025.09.096","article-title":"Influence of the combination of edaravone dexborneol and alteplase for intravenous thrombolysis on the efficacy and cognitive function of patients with acute cerebral infarction","volume":"10","author":"Hu","year":"2025","journal-title":"Syst Med"},{"key":"ref46","first-page":"509","article-title":"Effects of edarvone and borneol as adjuvant therapy on microcirculation and serum NO and SOD levels in patients with basilar artery perforator cerebral infarction","volume":"53","author":"Ding","year":"2025","journal-title":"Med Sci J Central South China"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14164\/j.cnki.cn11-5581\/r.2025.19:022","article-title":"Study on the effect of edaravone dexborneol combined with clopidogrel in the treatment of acute cerebral infarction","volume":"19","author":"Lu","year":"2025","journal-title":"Chin J Mod Drug Appl"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3969\/j.issn.1009-3257.2025.10.007","article-title":"Study on the effect of Xuesaitong combined with edaravone dexamethasone in patients with acute cerebral infarction and its impact on inflammatory factors","volume":"32","author":"Gao","year":"2025","journal-title":"J Rare and Uncommon Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.2096-3718.2025.07.001","article-title":"Efficacy of edaravone dexborneol in the treatment of acute cerebral infarction","volume":"9","author":"Gu","year":"2025","journal-title":"Modern Med Health Res"},{"key":"ref50","first-page":"55","article-title":"Efficacy and safety of edaravone dexborneol combined with butylphthalide sodium chloride in the treatment of acute cerebral infarction","volume":"10","author":"Shi","year":"2025","journal-title":"Clin Med Res Pract."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.19347\/j.cnki.2096-1413.202524017","article-title":"Effects of edaravone dexborneol injection combined with early intravenous thrombolysis on the short-term prognosis and neurological function of patients with acute ischemic stroke","volume":"10","author":"Chen","year":"2025","journal-title":"Clin Med Res Pract"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3969\/j.issn.1672-8157.2025.03.011","article-title":"Clinical effect of edaravone dexkanol combinedwith butylphthalide on treatment of patients with progressive cerebral infarction of perforator artery lesions","volume":"22","author":"Zhang","year":"2025","journal-title":"Chin J Drug Appl Monit"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15887\/j.cnki.13-1389\/r.2025.26.014","article-title":"Clinical effect of edaravone dexborneol combined with butylphthalide in the treatment of cerebral infarction and its influence on neurological function","volume":"18","author":"Hu","year":"2025","journal-title":"Chin J ofClinical Rational Drug Use"},{"key":"ref54","first-page":"68","article-title":"Clinical effect of edaravone dexborneol injection on acute cerebral infarction","volume":"23","author":"Wu","year":"2025","journal-title":"Contemp Medical Essays"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.19435\/j.1672-1721.2025.17:024","article-title":"Effects of edaravone dexborneol on neurological function and hemorheology in patients with acute cerebral infarction after intravenous thrombolysis","volume":"29","author":"Li","year":"2025","journal-title":"Primary Med Forum"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3969\/j.issn.2096-3327.2025.10.011","article-title":"Clinical study of edaravone dexborneol combined with tirofiban in the treatment of progressive small artery occlusive cerebral infarction","volume":"22","author":"Zhao","year":"2025","journal-title":"Chin J Ration Druguse"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3969\/j.issn.1672-0369.2025.08:006","article-title":"Effects of butylphthalide combined with edaravone dextrogenol in treatment of patients with lacunar cerebral infarction","volume":"37","author":"Wang","year":"2025","journal-title":"Med J Chin People Health"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3969\/j.issn.1674-3245.2025.02:005","article-title":"Effect of edaravone dextrocamphorol on nerve function, cerebral blood perfusion and inflammatory state in acute cerebral infarction","volume":"27","author":"Yao","year":"2025","journal-title":"Chin J Health Care Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.14163\/j.cnki.11-5547\/r.2025.05.021","article-title":"Effect observation of alteplase combined with edaravone and dexborneol in the treatment of patients with acute cerebral infarction","volume":"20","author":"Hu","year":"2025","journal-title":"China Prac Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3969\/j.issn.2096-3718.2025.02","article-title":"Efficacy of edaravone dexborneol combined with butylphthalide in the treatment of acute cerebral infarction and its impact on patients' neurological function","volume":"9","author":"Xia","year":"2025","journal-title":"Mod Med Health Res"},{"key":"ref61","first-page":"1228","article-title":"Edaravone dexborneol combined with ureklin on the prognosis of acute cerebral infarction patients","volume":"49","author":"Xu","year":"2025","journal-title":"Gui Zhou Yi Yao"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3969\/j.issn.1674-4721.2025.04.10","article-title":"Clinical effect of butylphthalide injection combined with Edaravone and Dexborneol in the treatment of acute cerebral infarction","volume":"32","author":"Xu","year":"2025","journal-title":"China Mod Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20072\/j.cnki.issn2097-0196.2025.02.010","article-title":"Efficacy of Edaravone Dexborneol combined with Atipuase for intravenous thrombolysis in the treatment of acute cerebral infarction","volume":"24","author":"Guo","year":"2025","journal-title":"An Hui Yi Zhuan Xue Bao"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.20235\/j.issn.2095-1752.2025.22.013","article-title":"Effects of Edaravone and Dextrorphanol on neurological function, serum DKK1 and vascular endothelial function in patients with acute cerebral infarction","volume":"15","author":"Homg","year":"2025","journal-title":"Yi Yao Qian Yan"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1005-9202.2025.06.004","article-title":"Therapeutic efficacy of rhTNK-tPA combined with Edaravone Dexborneol in elderly patients with acute cerebral infarction","volume":"45","author":"Wang","year":"2025","journal-title":"China Geriatr J"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3969\/j.issn.1005-8982.2025.14.004","article-title":"Efficacy of edaravone dexborneol concentrated solution combined with butylphthalide sodium chloride injection in the treatment of elderly patients with acute anterior circulation infarction and its impact on prognosis","volume":"35","author":"Zhou","year":"2025","journal-title":"China J Mod Med"},{"key":"ref67","first-page":"369","volume-title":"J Clin Neurol","author":"Yue","year":"2025"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"e086850","DOI":"10.1136\/bmj-2025-086850","article-title":"Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial","volume":"392","author":"Wang","year":"2026","journal-title":"BMJ"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamaneurol.2019.5061","article-title":"Distributional validity and prognostic power of the national institutes of health stroke scale in US administrative claims data","volume":"77","author":"Saber","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(16)30962-X","article-title":"Stroke","volume":"389","author":"Hankey","year":"2017","journal-title":"Lancet"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e17986","DOI":"10.1016\/j.heliyon.2023.e17986","article-title":"Neuroinflammation and anti-inflammatory therapy for ischemic stroke","volume":"9","author":"Cao","year":"2023","journal-title":"Heliyon"},{"key":"ref72","first-page":"938","article-title":"Scientific statements on brain cytoprotection in ischemic stroke\u2014\u2014a scientific statement from the Chinese Stroke Association","volume":"19","author":"Lu","year":"2024","journal-title":"Chin J Stroke"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000069318","article-title":"Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters","volume":"15","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2014.05.051","article-title":"Edaravone protected PC12 cells against MPP(+)-cytoxicity via inhibiting oxidative stress and up-regulating heme oxygenase-1 expression","volume":"343","author":"Cheng","year":"2014","journal-title":"J Neurol Sci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"111700","DOI":"10.1016\/j.intimp.2024.111700","article-title":"Edaravone dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration","volume":"130","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"9569","DOI":"10.1007\/s00210-025-03950-1","article-title":"Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis of randomized controlled trials","volume":"398","author":"Kashbour","year":"2025","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref77","author":"Zhong","year":"2024"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","article-title":"Quality of life after TIA and stroke: ten-year results of the Oxford vascular study","volume":"81","author":"Luengo-Fernandez","year":"2013","journal-title":"Neurology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/00207454.2026.2628832","article-title":"Evaluating the efficacy and safety of Edaravone-Dexborneol in acute ischemic stroke: an updated systematic review and meta-analysis of 7,846 Chinese patients","volume":"136","author":"Sabet","year":"2026","journal-title":"Int J Neurosci"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-026-05439-x","article-title":"Edaravone dexborneol in acute ischemic stroke: a systematic review and meta-analysis of randomized trials with clinical and thrombectomy-specific subgroup analyses","volume":"1","author":"Tariq","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1794547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:49:26Z","timestamp":1787719766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1794547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":80,"alternative-id":["10.3389\/fneur.2026.1794547"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1794547","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1794547"}}